Abstract
Background: Since its FDA approval in 2006, the Human papillomavirus (HPV) vaccine has been politically-charged, given its association with sexual health among young women and its history of controversial, and largely unsuccessful, legislative mandates. The extent to which perceived politicization is related to public support for the vaccine's use, however, is not clear. We sought to examine the relationship between public perceptions of politicization of the HPV vaccine and public support for HPV vaccine policies. Methods: We fielded a survey from May-June 2016 using a nationally representative sample of U.S. adults (18–59 years). Among respondents aware of the HPV vaccine (n = 290), we predict support for HPV vaccine policies based on respondents’ perceptions of three characteristics of the vaccine's portrayal in public discourse: degree of controversy, certainty of the scientific evidence supporting the vaccine's use, and frequency with which the vaccine appears in political discussion. Results: Respondents who perceived greater certainty about the scientific evidence for the HPV vaccine were more supportive of HPV vaccine policies (p < 0.0001) than respondents who perceived the scientific evidence to be uncertain, after adjusting for respondents’ characteristics, including demographics and partisanship. Conclusions: Public perceptions of the HPV vaccine's politicization, particularly the portrayal of scientific evidence, are associated with receptivity to legislative mandates. Policy implications: How the certainty of a body of evidence gets communicated to the public may influence the policy process for a critical cancer prevention intervention.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 5121-5128 |
| Number of pages | 8 |
| Journal | Vaccine |
| Volume | 37 |
| Issue number | 35 |
| DOIs | |
| State | Published - Aug 14 2019 |
Bibliographical note
Funding Information:This study was funded, in part, by a Research Scholar Grant from the American Cancer Society ( RSG-14-166-01-CPPB ) (PI: Gollust). R.H. Nagler also acknowledges support from the Building Interdisciplinary Research Careers in Women’s Health Grant ( K12-HD055887 ) from the Eunice Kennedy Shriver National Institutes of Child Health and Human Development , the Office of Research on Women’s Health , and the National Institute on Aging , administered by the University of Minnesota Women’s Health Research Program. The study sponsors had no role in study design; collection, analysis, and interpretation of data; writing the report; nor the decision to submit the report for publication.
Funding Information:
This study was funded, in part, by a Research Scholar Grant from the American Cancer Society (RSG-14-166-01-CPPB) (PI: Gollust). R.H. Nagler also acknowledges support from the Building Interdisciplinary Research Careers in Women's Health Grant (K12-HD055887) from the Eunice Kennedy Shriver National Institutes of Child Health and Human Development, the Office of Research on Women's Health, and the National Institute on Aging, administered by the University of Minnesota Women's Health Research Program. The study sponsors had no role in study design; collection, analysis, and interpretation of data; writing the report; nor the decision to submit the report for publication.
Keywords
- Cancer prevention
- HPV vaccine
- Health policy
- Legislation
- Politics
- Public health
